Wall Street brokerages expect Melinta Therapeutics Inc (NASDAQ:MLNT) to report ($2.73) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Melinta Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.86) and the lowest estimate coming in at ($3.59). Melinta Therapeutics posted earnings of ($4.75) per share in the same quarter last year, which suggests a positive year over year growth rate of 42.5%. The business is scheduled to issue its next earnings results after the market closes on Thursday, May 9th.
On average, analysts expect that Melinta Therapeutics will report full year earnings of ($10.31) per share for the current year, with EPS estimates ranging from ($13.26) to ($7.91). For the next financial year, analysts forecast that the business will post earnings of ($5.57) per share, with EPS estimates ranging from ($9.69) to ($2.80). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Melinta Therapeutics.
Melinta Therapeutics (NASDAQ:MLNT) last issued its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($1.93) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.92). The company had revenue of $35.49 million during the quarter, compared to analysts’ expectations of $17.77 million. Melinta Therapeutics had a negative return on equity of 60.83% and a negative net margin of 163.01%.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Melinta Therapeutics by 4.4% in the 4th quarter. BlackRock Inc. now owns 2,532,235 shares of the biotechnology company’s stock valued at $2,008,000 after purchasing an additional 106,721 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Melinta Therapeutics by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,770,765 shares of the biotechnology company’s stock worth $6,995,000 after acquiring an additional 76,253 shares during the last quarter. Vanguard Group Inc lifted its stake in shares of Melinta Therapeutics by 4.5% during the 3rd quarter. Vanguard Group Inc now owns 1,770,765 shares of the biotechnology company’s stock worth $6,995,000 after acquiring an additional 76,253 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Melinta Therapeutics by 6.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 772,725 shares of the biotechnology company’s stock worth $613,000 after acquiring an additional 48,907 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Melinta Therapeutics by 979.8% during the 4th quarter. Deutsche Bank AG now owns 751,625 shares of the biotechnology company’s stock worth $595,000 after acquiring an additional 682,014 shares during the last quarter.
MLNT traded down $0.20 during midday trading on Friday, reaching $4.39. The company had a trading volume of 452 shares, compared to its average volume of 435,692. The company has a quick ratio of 0.81, a current ratio of 1.12 and a debt-to-equity ratio of 0.58. The stock has a market cap of $51.77 million, a price-to-earnings ratio of -0.25 and a beta of 2.31. Melinta Therapeutics has a 1 year low of $3.20 and a 1 year high of $46.00.
Melinta Therapeutics Company Profile
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.
Further Reading: What is Depreciation?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.